<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT2016081128944N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2016-08-11</date_registration>
      <primary_sponsor>Ahvaz Jundishapur University Of Medical Sciences, Ahvaz, Iran</primary_sponsor>
      <public_title>Compare the efficacy of Metoclopramide and Dexamethasone with Metoclopramide itself in the control of vomiting due to mild head trauma in children between the ages of 8-2 years</public_title>
      <acronym></acronym>
      <scientific_title>Comparison of Metoclopramide and Dexamethasone versus Metoclopramide itself in the control of vomiting due to  minor head trauma in the age range of  2-8 years old</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2016-07-26</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>60</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/23368</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment.</study_design>
      <phase>N/A</phase>
      <hc_freetext>vomiting caused by minor head trauma.</hc_freetext>
      <i_freetext>Intervention 1: The intervention group &#13;
  In this study, one group of patients will receive 0.15mg/kg Metoclopramide and also 0.15 mg/kg Dexamethazone intramuscularly. Then, after 20,40 and 60 minutes, and also each hour (until 4 hours after the intervention) the patients' vital signs including ( blood pressure, respiratory rate, heart rate, blood oxygen concentration), the consciousness level of patients and vomiting intensity changes will be measured and recorded. If the patient is discharged from the hospital, he/she will receive a phone call for follow for up to 24 hours. Finally, the differences in these parameters between the two groups will be examined. If the both groups will not respond to the therapeutic intervention or they have deterioration in general condition, other lines of treatment or repetition of the intervention should be considered. If it will happen before the first 20 minutes after intervention, she/he will be excluded. The data from the assessment will be analyzed by SPSS software version 22. Intervention 2: Control group: In this study, this group will receive 0.15mg/kg Metoclopramide and also, 0.15mg/kg distilled water (Placebo) intramuscular. Then, after 20, 40 and 60 minutes, and also each hour (until 4 hours after intervention) the vital signs of patients including ( blood pressure, respiratory rate, heart rate, blood oxygen concentration) , the consciousness of patients and vomiting intensity changes will be measured and recorded. If the patient is discharged from the hospital, he/she will have a telephone call for follow up until 24 hours. Finally, the differences in these parameters between the two groups will be examined. If the both groups had not an appropriate response to the therapeutic intervention, and if their general condition will be deteriorate, other lines of treatment or repetition of the intervention will be done. If patients need other treatment before 20 minute, they will be excluded from the study.  The data from the assessment will be analyzed by SPSS software version 22.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan></results_IPD_plan>
      <results_IPD_description></results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Mahdis vakili</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Ahvaz Jundishapur University Of Medical Sciences, Golestan Ave.</address>
        <city>Ahvaz</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip></zip>
        <telephone>+98 61 3336 7543</telephone>
        <email>mahdisvakili@yahoo.com</email>
        <affiliation>Ahvaz Jundishapur University Of Medical Sciences, Ahvaz, Iran</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Seyed Mohammad Kazem Mortazavis</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Ahvaz Jundishapur University Of Medical Sciences, Golestan Ave.</address>
        <city>Ahvaz</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip></zip>
        <telephone>+98 61 3336 7543</telephone>
        <email>eltemas2a1000@yahoo.com</email>
        <affiliation>Ahvaz Jundishapur University Of Medical Sciences, Ahvaz, Iran</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Inclusion criteria: Patients with GCS 14-15; aged between 2-8 years;  minor trauma associated with vomiting and normal CT. &#13;
 Exclusion criteria: unstable hemodynamics; neurological disorders; restless leg syndrome; the use of antiemetic medications during past 8 hours; recent receipt of  injectable drugs; Nausea and vomiting caused by motion sickness; chemotherapy and radiotherapy; allergy to metoclopramide or dexamethasone;  having contraindications for dexamethasone; simultaneous treatment with corticosteroids; diarrhea and  a child who is under treatment with sedative drugs.</inclusion_criteria>
      <agemin>2 years</agemin>
      <agemax>6 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria></exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>F50.5</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Vomiting associated with other psychological disturbances</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>The intervention group &#13;
  In this study, one group of patients will receive 0.15mg/kg Metoclopramide and also 0.15 mg/kg Dexamethazone intramuscularly. Then, after 20,40 and 60 minutes, and also each hour (until 4 hours after the intervention) the patients' vital signs including ( blood pressure, respiratory rate, heart rate, blood oxygen concentration), the consciousness level of patients and vomiting intensity changes will be measured and recorded. If the patient is discharged from the hospital, he/she will receive a phone call for follow for up to 24 hours. Finally, the differences in these parameters between the two groups will be examined. If the both groups will not respond to the therapeutic intervention or they have deterioration in general condition, other lines of treatment or repetition of the intervention should be considered. If it will happen before the first 20 minutes after intervention, she/he will be excluded. The data from the assessment will be analyzed by SPSS software version 22.</i_keyword>
      <i_keyword>Control group: In this study, this group will receive 0.15mg/kg Metoclopramide and also, 0.15mg/kg distilled water (Placebo) intramuscular. Then, after 20, 40 and 60 minutes, and also each hour (until 4 hours after intervention) the vital signs of patients including ( blood pressure, respiratory rate, heart rate, blood oxygen concentration) , the consciousness of patients and vomiting intensity changes will be measured and recorded. If the patient is discharged from the hospital, he/she will have a telephone call for follow up until 24 hours. Finally, the differences in these parameters between the two groups will be examined. If the both groups had not an appropriate response to the therapeutic intervention, and if their general condition will be deteriorate, other lines of treatment or repetition of the intervention will be done. If patients need other treatment before 20 minute, they will be excluded from the study.  The data from the assessment will be analyzed by SPSS software version 22.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Vomiting caused by minor head trauma. Timepoint: 20 minutes before the Intervention. Method of measurement: VAS test.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Vital signs (respiratory rate, heart rate) and their alertness. Timepoint: after 20,40 and 60 minutes, and also hourly (until 4 hours after the intervention of patients' vital signs). Method of measurement: Pulse Oximeter, manometer, counting the respiratory rate.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Ahvaz Jundishapur University Of Medical Sciences, Ahvaz, Iran</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2016-06-14</approval_date>
        <contact_name>Ahvaz Jundishapur University Of Medical Sciences, Ahvaz, Iran</contact_name>
        <contact_address>Ahvaz Jundishapur University Of Medical Sciences, Golestan Ave. Ahvaz  Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
